title: A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression.
abstract: The effect of selective serotonin receptor inhibitors (SSRIs) on healthy individuals remains unclear. The aim of the trial was to evaluate the effect of the SSRI escitalopram on cognitive function in healthy first-degree relatives of patients with major depressive disorder (FDRs). A total of 80 FDRs were randomized to escitalopram (10 mg/day) (n = 41) versus placebo (n = 39) for 4 weeks. Neuropsychological tests and ratings of mood were applied at entry (T0) and at 4 weeks (T4). The main outcome measure was calculated as the change (T4-T0) in a general cognition score, which was the standardized mean of 13 test measures. Mean change in the general cognition score was not significantly increased with escitalopram compared with placebo (p = 0.37) or for any of the specific tests. In univariate analyses no statistically significant correlations were found between change in the general cognitive score and the variables age, sex, Hamilton depression score 17 items, Danish Adult Reading Test-45, and plasma escitalopram levels, respectively. These results suggest that treatment with escitalopram does not improve or impair cognitive function in FDRs. Improvement in cognitive function following treatment of depressed patients with SSRIs seems to be related to the effects on depressive symptoms rather than to a direct effect of the SSRI.
authors: Psychiatric Centre of Copenhagen, Rigshospitalet, University Hospital of Copenhagen, Denmark.
authors: Ulla
authors: U
authors: Knorr
authors: Maj
authors: M
authors: Vinberg
authors: Anders
authors: A
authors: Gade
authors: Per
authors: P
authors: Winkel
authors: Christian
authors: C
authors: Gluud
authors: Jørn
authors: J
authors: Wetterslev
authors: Ulrik
authors: U
authors: Gether
authors: Lars
authors: L
authors: Kessing
keywords: cognitive function; escitalopram; healthy; high risk; major depressive disorder; placebo-controlled; trial
references: Arch Gen Psychiatry. 1961 Jun;4:561-71
references: 13688369
references: Int J Neuropsychopharmacol. 2009 Mar;12(2):169-79
references: 18752726
references: Nord J Psychiatry. 2010 May 4;64(3):153-63
references: 20088752
references: Psychopharmacology (Berl). 2003 Jul;168(3):293-8
references: 12692706
references: J Clin Pharmacol. 2005 Dec;45(12):1400-6
references: 16291715
references: J Clin Psychiatry. 2005 Apr;66(4):436-43
references: 15816785
references: J Psychopharmacol. 2001 Sep;15(3):173-9
references: 11565624
references: Nord J Psychiatry. 2001;55 Suppl 44:5-69
references: 11860666
references: Am J Psychiatry. 2004 Jul;161(7):1256-63
references: 15229059
references: Ann N Y Acad Sci. 1997 Jan 15;807:492-3
references: 9071379
references: Arch Gen Psychiatry. 1990 Jun;47(6):589-93
references: 2190539
references: Br J Psychiatry. 1986 Dec;149:698-709
references: 3790869
references: Acta Psychiatr Scand Suppl. 1986;326:1-37
references: 3458353
references: Trials. 2009 Aug 11;10:66
references: 19671139
references: Br J Psychiatry. 2001 Mar;178:200-6
references: 11230029
references: Psychopharmacology (Berl). 2009 Dec;207(2):213-23
references: 19756527
references: N Engl J Med. 2008 Jan 17;358(3):252-60
references: 18199864
references: Psychopharmacology (Berl). 2002 Apr;160(4):381-6
references: 11919665
references: Control Clin Trials. 1996 Aug;17(4):285-90; discussion 290-3
references: 8889343
references: Br J Clin Pharmacol. 1995 Apr;39(4):397-404
references: 7640146
references: Acta Neurol Scand. 1988 Apr;77(4):293-306
references: 3389080
references: J Psychopharmacol. 2002 Sep;16(3):207-14
references: 12236626
references: PLoS One. 2011;6(6):e21224
references: 21738622
references: J Hepatol. 2007 May;46(5):947-54
references: 17412447
references: Aviat Space Environ Med. 2002 Oct;73(10):964-70
references: 12398257
references: Neuroimage. 2007 Sep 1;37(3):904-11
references: 17625917
references: Am J Psychiatry. 2009 Oct;166(10):1178-84
references: 19755572
references: Hum Psychopharmacol. 2006 Oct;21(7):473-9
references: 17029307
references: Psychol Med. 2009 May;39(5):757-62
references: 18775088
references: J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):285-95
references: 8158175
references: BMJ. 2001 Nov 10;323(7321):1123-4
references: 11701584
references: Neuroimage. 2005 Aug 15;27(2):299-313
references: 15950492
references: J Affect Disord. 2011 Nov;134(1-3):20-31
references: 21163534
references: Am J Psychiatry. 1998 Mar;155(3):373-9
references: 9501748
references: Psychol Med. 1998 Sep;28(5):1027-38
references: 9794010
references: Psychol Med. 2006 Aug;36(8):1119-29
references: 16734950
references: Pharmacopsychiatry. 2006 Jul;39(4):128-34
references: 16871468
references: Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(1):63-80
references: 3259002
references: Psychopharmacology (Berl). 2008 Jan;195(4):487-96
references: 17874333
references: Cortex. 1978 Jun;14(2):234-44
references: 679704
references: J Psychopharmacol. 2002 Dec;16(4):321-31
references: 12503831
references: Eur J Pharmacol. 2010 Jan 10;626(1):72-82
references: 19837053
references: Aviat Space Environ Med. 2007 Jul;78(7):693-7
references: 17679567
references: J Psychopharmacol. 2005 Jan;19(1):12-20
references: 15671124
references: Eur Neuropsychopharmacol. 1995 Mar;5(1):35-42
references: 7613099
references: Br J Psychiatry. 2009 Aug;195(2):102-8
references: 19648538
references: Scand J Psychol. 2002 Jul;43(3):239-51
references: 12184479
references: Lancet. 2009 Feb 28;373(9665):746-58
references: 19185342